Industry Insights on Oligonucleotide APIs Nusinersen & Inclisiran
November 7, 2025
RNA-based therapeutics are rapidly reshaping modern medicine. More than 20 oligonucleotide drugs are now FDA approved, including multiple antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers. These approvals span a growing range of therapeutic areas, from rare neuromuscular disorders to high-prevalence cardiovascular and metabolic diseases.
Expanding the RNA Medicine Frontier
While the potential of RNA therapeutics is expanding quickly, the complexity of chemical synthesis, purification, and analytical control of oligonucleotides has also grown. As a result, specialized oligonucleotide CDMOs have become essential partners in enabling drug quality, regulatory compliance, and commercial scalability.
How RNA Therapeutics Work
Oligonucleotide therapies modulate gene expression at the RNA level with high precision. A few core mechanisms include:
- ASOs: Modify splicing or block translation of harmful transcripts
- SiRNAs: Engage the RNA-induced silencing complex to degrade target mRNA
- Targeted delivery ligands (e.g., GalNAc): Enable liver-specific uptake for metabolic diseases
These programmable modalities allow developers to reach targets once considered “undruggable” using traditional small molecules or biologics.
RUO Supply and Regulatory Compliance
“Research Use Only” clearly defines non-clinical intent:
For developers planning ahead for IND-enabling work, high-quality RUO material provides a critical foundation for method development and process optimization.
Evolving Role of Oligonucleotide CDMO Partners
Oligonucleotide CDMOs play a vital role in translating RNA therapeutic concepts into CGMP-compliant drug manufacturing processes. These specialized manufacturers provide the analytical and process development expertise needed to scale complex molecules such as antisense and siRNA therapies, while ensuring quality, consistency, and regulatory alignment.
With the growing demand for bringing innovative oligo therapies to market, experienced CDMO partners become increasingly pivotal for enabling reliable, high-purity global supply that supports IND readiness and commercial success in API manufacturing.
Case examples such as nusinersen and inclisiran highlight how advancing oligonucleotide innovation relies on precise oligonucleotide synthesis, advanced conjugation capabilities, and rigorous analytics — all core strengths of leading CDMOs.
As RNA therapies continue progressing through clinical development and commercialization, oligonucleotide CDMOs are paving the technical, regulatory, and GMP manufacturing frameworks that will drive the next generation of life-saving therapeutics for patients worldwide.
Latest News & Resources
Oligonucleotide CDMO Insights
Latest Oligonucleotide Manufacturing News from CPC Scientific
TIDES EU is the leading conference in Europe connecting innovators in oligonucleotide and mRNA therapeutics. If you’ll be in Switzerland, we’d love to meet you there!
From Nov. 11–13, join CPC Scientific’s experts at Booth #327 to discuss the latest developments in oligo manufacturing.
As an industry leader in late-phase and commercial oligonucleotide manufacturing, we provide contract development and manufacturing of custom oligos, including scale-up and analytical testing. Our oligo expertise, with a broad range of modifications, allows us to deliver tailored solutions...
We offer both research-grade and clinical-grade oligonucleotide manufacturing services. Using solid-phase synthesis, we provide custom oligo development, scale-up, and analytical testing, supporting clients across the entire lifecycle from early discovery through clinical stages...
CPC Scientific offers an integrated solution for peptide–oligo conjugate manufacturing, with fully in-house peptide, oligo, and POC capabilities. Our end-to-end POC platform streamlines development, reduces outsourcing risks, and ensures quality across the entire development continuum.
As an industry leader in late-phase and commercial oligonucleotide manufacturing, we provide contract development and manufacturing of custom oligos, including scale-up and analytical testing. Our oligo expertise, with a broad range of modifications, allows us to deliver tailored solutions...
We offer both research-grade and clinical-grade oligonucleotide manufacturing services. Using solid-phase synthesis, we provide custom oligo development, scale-up, and analytical testing, supporting clients across the entire lifecycle from early discovery through clinical stages...
CPC Scientific offers an integrated solution for peptide–oligo conjugate manufacturing, with fully in-house peptide, oligo, and POC capabilities. Our end-to-end POC platform streamlines development, reduces outsourcing risks, and ensures quality across the entire development continuum.